Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in

Byung Hee Han1, Meng-Liang Zhou2, Andrew W Johnson2

  • 1Departments of Neurological Surgery, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110.

Insights

Reactive oxygen species (ROS) drive cerebral amyloid angiopathy (CAA) and related cerebrovascular deficits. Targeting ROS, particularly NADPH oxidase, may offer a novel therapeutic strategy for CAA and Alzheimer's Disease (AD).

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Oxidative Stress Research

Background:

  • Cerebral amyloid angiopathy (CAA) involves amyloid-beta deposition in cerebral arteries, leading to hemorrhage, stroke, and cognitive decline.
  • While oxidative stress from soluble amyloid-beta is understood, the mechanisms of insoluble CAA-induced cerebrovascular (CV) dysfunction remain unclear.

Purpose of the Study:

  • To investigate the role of reactive oxygen species (ROS) in mediating CAA-induced CV deficits.
  • To explore potential therapeutic strategies targeting ROS for CAA and associated conditions like Alzheimer's Disease (AD).

Main Methods:

  • Utilized aged Tg2576 mice, a model for amyloidosis.
  • Administered NADPH oxidase inhibitor (apocynin) and ROS scavenger (tempol).
  • Assessed oxidative stress, CV reactivity, CAA formation, microhemorrhage, and ApoE expression.

Main Results:

  • Apocynin and tempol reduced oxidative stress and improved CV reactivity in aged Tg2576 mice.
  • Anti-ROS therapy decreased CAA formation and mitigated CAA-induced vasomotor impairment.
  • Therapy also attenuated CAA-related microhemorrhage and reduced ApoE expression, a factor in CAA formation.

Conclusions:

  • ROS, particularly from NADPH oxidase, are key mediators of CAA formation, CV dysfunction, and microhemorrhage.
  • Targeting ROS represents a promising therapeutic avenue for patients with CAA and AD.

Related Concept Videos